Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Primary Care
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
Outside of teplizumab, what therapies do you recommend for preserving beta cell function in patients with early stage type 1 diabetes mellitus?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
Is there a role for intermittent fasting as part of the management of a patient with long-standing type 2 diabetes and consistently poor glycemic control despite maximal therapy?
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
How do you counsel patients on the use of compounded weight loss medications?
Do you regularly counsel younger women of childbearing age about the impact of Tirzepatide on oral hormonal contraception?
How do you approach the use of metformin in the management of prediabetes for patients who are neither obese nor have a family history of diabetes?
When do you recommend screening patients with T2DM for heart failure?
What is the therapeutic role and blood glucose lowering capability of bromocriptine and cholestyramine for the treatment of Type 2 diabetes?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
